The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 89 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 0.1 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language, runway < 6 months) coexists with live selling machinery (atm program, equity line, shelf filed). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 33 |
| Aug 10, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-10 filing | 27 |
| Aug 7, 2026 | ▼ Shelf filed | S-1 filed 2026-08-07 filing | 32 |
| Aug 5, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-05 (accepted 16:37 ET) filing | 32 |
| Jul 29, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-29 (accepted 16:17 ET) filing | 32 |
| Jul 29, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-07-29 (accepted 16:17 ET) filing | 27 |
| Jul 23, 2026 | ▼ Equity line | “equity line” language in 8-K (8-K) filed 2026-07-23 filing | 45 |
| Jul 23, 2026 | ▼ ATM program | “atm” language in 8-K (EX-10.1) filed 2026-07-23 filing | 44 |
| Jul 23, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-23 (accepted 17:30 ET) filing | 35 |
| Jul 23, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-07-23 filing | 32 |
| Jul 23, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-10.1) filed 2026-07-23 filing | 32 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.1 months runway: liquidity $39,221 as of 2026-06-30, burn $5,889,056/yr (annualized 272-day YTD operating cash flow [companyfacts]) filing | 51 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 12,047,651 (2026-05-11) -> 19,946,803 (2026-08-10), +66% filing | 36 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $5,482,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 26 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $39,221 vs current liabilities $4,593,051 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →